JPMorgan stock edges up as tariff headlines and bank-specific news collide

February 20, 2026
JPMorgan stock edges up as tariff headlines and bank-specific news collide

New York, Feb 20, 2026, 15:09 (ET) — Regular session

JPMorgan Chase & Co climbed roughly 0.6% Friday, with shares changing hands at $309.76 during afternoon trading in New York. The stock swung from a low of $305.83 to as high as $310.94 earlier in the session.

The shares edged up, following a move higher in U.S. stocks after the Supreme Court overturned President Donald Trump’s broad tariffs. Investors were still contending with sluggish GDP numbers and stronger inflation. “Striking down of these tariffs will benefit corporate bottom lines, corporate earnings,” said Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder in New York. Reuters

Why it matters now: Trade policy risk is finding its way back into valuations. Trump’s proposal? A 10% global tariff for 150 days, citing Section 122 of the Trade Act of 1974, along with fresh Section 301 probes. These moves could keep markets on edge—and rate bets unsettled.

Big U.S. banks headed in separate directions. Wells Fargo picked up around 0.6%, Citigroup dropped close to 0.5%. Bank of America held steady, and Goldman Sachs barely budged.

JPMorgan is adding staff to support its $1.5 trillion Security & Resiliency Initiative, a decade-long push rolled out in October targeting industries linked to U.S. national security and economic resilience. According to a memo reviewed by Reuters, new hires include Kevin Quinn, formerly of the CHIPS Program Office, plus executives brought in for defense, aerospace, and a team zeroing in on supply-chain weak spots.

This week, the bank announced plans to roll out over 160 new branches in 2026, covering more than 30 states. It’s also targeting close to 600 branch renovations and expects to add 1,100 jobs. “Chase branches are more than just a place to transact; they are vital engines driving economic activity,” said Tom Horne, who leads consumer branch banking. Reuters

Regulators tossed in an extra complication. The European Central Bank hit JPMorgan’s European unit with a 12.18 million euro fine, citing misreported capital requirements after the bank botched its risk-weighted asset calculation—a metric tied directly to how much capital banks have to hold for possible losses. JPMorgan says it has corrected the problem. A spokesperson added the unit “proactively identified and self-reported the issues.” Reuters

JPMorgan, in a U.S. court filing, argued that Trump shouldn’t have singled out CEO Jamie Dimon as a defendant in his suit over shuttered accounts from 2021—a move the bank claims was aimed at keeping the case at the state level. Trump’s legal spokesperson countered, telling Reuters the action was prompted by what they called the bank’s efforts to “debank and blacklist” Trump. Reuters

Insider selling cropped up in a recent Form 4: Troy L. Rohrbaugh, co-CEO of JPMorgan’s commercial and investment bank, unloaded 50,000 shares on Feb. 19, averaging $307.1134 apiece under a 10b5-1 pre-set trading plan. That move trimmed his directly held stake to 111,279 shares.

Still, bulls face a catch: tariff shocks and unexpected inflation data can jolt Treasury yields, dragging major banks along for the ride. Layer on the steady stream of regulatory and legal news, and that smooth climb can get rough in a hurry.

JPMorgan’s next company update lands in New York on Monday, Feb. 23, set for 4:30 p.m. ET. Investors are eyeing a firm overview plus a Q&A with executive management.

Technology News Today

  • Novo Nordisk CEO: OpenAI partnership to speed drug discovery and Wegovy confidence
    April 14, 2026, 7:21 AM EDT. Maziar Mike Doustdar, Novo Nordisk's chief executive, said an AI partnership with OpenAI will speed drug discovery and delivery, improve accuracy and bolster confidence in Wegovy - Novo Nordisk's obesity drug (brand name for semaglutide) - even as rivals press for pace. The collaboration aims to shorten research cycles from target identification to clinical testing by using advanced data modeling and automation. Wegovy has broad adoption in the U.S. and Europe, but competition in weight-management therapies is rising. The remarks reflect Novo Nordisk's push to fuse science with speed and scale, trimming development timelines while safeguarding safety and efficacy.